Skip to main content

bcl-2 inhibitor bgb-21447

Generic: Bcl-2 Inhibitor BGB-21447

bcl-2 inhibitor bgb-21447: 2 clinical trials tracked.

bcl-2 inhibitor bgb-21447 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about bcl-2 inhibitor bgb-21447, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Metastatic Breast Cancer
Clinical Trial Registry Records (2)

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer

NCT06756932Registry updated 2026-09-14·Phase 1·ONC
Recruiting

Primary endpoint: Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

Interventionalopen120 targetStarted 2025-02Completion 2027-0714 sites · Australia, China, United StatesBeOne Medicines

A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies

NCT05828589Registry updated 2026-07-14·Phase 1·ONC
Terminated

Primary endpoint: Part 1: Number of participants with dose limiting toxicities (DLTs)

InterventionalRandomizedopen51 enrolledStarted 2023-06Completion 2026-0628 sites · Australia, China, New Zealand, United StatesBeOne Medicines